novartis_outside_1

Novartis’ Sandoz scores EU approval for Remicade biosimilar

pharmafile | May 24, 2018 | News story | Sales and Marketing EU, Europe, Novartis, Remicade, Sandoz, Zessly, pharma 

The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s Remicade (infliximab) and other products, known as Zessly.

The therapy has been authorised in all the indications of its reference product, which includes the treatment of rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, adult ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

The decision was based on data showing that Zessly matched its reference product in terms of safety, efficacy and quality, and marks the sixth biosimilar approval for the firm.

“The European Commission approval for Zessly is a key milestone in bringing this important medicine to appropriate patients,” commented Sandoz CEO Richard Francis. “Biosimilars, such as Zessly, help to address a significant unmet need for earlier patient access to biologic medicines and are at the heart of our Sandoz commitment to improving and extending lives.”

Matt Fellows

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

FDA approves Sandoz’s denosumab biosimilars

Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Latest content